Tag: SARS-CoV-2 vaccine

Posted on

Annual COVID Vaccinations Might be Required

external content.duckduckgo 6

the staff of the Ridgewood blog

Ridgewood NJ, Pfizer CEO Albert Bourla recently said people likely will need to get a third dose of the company’s SARS-CoV-2 vaccine within 12 months of completing their vaccinations. He speculated that annual vaccinations might be required but more research needs to be completed to confirm his predictions. Bourla’s comments were made on April 1 at a CVS Health event but were released April 15. That same day at a US House Select Subcommittee on the Coronavirus Crisis hearing, Chief Science Officer of the White House COVID-19 Response Team Dr. David Kessler noted the emergence of variants of concern will challenge available vaccines’ effectiveness, probably requiring booster shots. However, Dr. Kessler also stated additional research is needed to understand timing and necessity.

Posted on

US National Institute of Allergy and Infectious Diseases Questions AstraZeneca COVID vaccine’s Efficacy Estimate

AstraZeneca Oxford vaccine 900x506 1
the staff of the Ridgewood blog
Ridgewood NJ, according to Johns Hopkins Center for Health Security, AstraZeneca announced preliminary results from a Phase 3 clinical trial for its SARS-CoV-2 vaccine, developed in collaboration with the University of Oxford. The trial included more than 32,000 participants in Chile, Peru, and the US, including 21,583 who received at least one dose of the vaccine. The press release reports an overall efficacy of 79% against any COVID-19 disease among all age groups and 80% efficacy for adults aged 65 years and older. Additionally, the press release describes 100% efficacy against severe disease and hospitalization. AstraZeneca explicitly noted that an independent review of the safety data “found no increased risk of thrombosis or events characterized by thrombosis” associated with the vaccine. Previous analysis of data from trials in Brazil, South Africa, and the UK estimated the overall efficacy to be 60%.

Continue reading US National Institute of Allergy and Infectious Diseases Questions AstraZeneca COVID vaccine’s Efficacy Estimate

Posted on

AstraZeneca’s COVID19 Vaccine Trial Paused Over Safety Concerns

AstraZeneca

the staff of the Ridgewood blog

Oxford UK, The Phase 3 clinical trial for AstraZeneca’s candidate SARS-CoV-2 vaccine (developed in collaboration with Oxford University) has been paused following the identification of a serious adverse event in one of the participants. Neither AstraZeneca nor Oxford University have yet disclosed details of the adverse event, which reportedly occurred in the UK; however, The New York Times reports that the patient developed transverse myelitis. It has not yet been determined whether the condition was associated with the vaccine. An earlier clinical trial for the AstraZeneca vaccine was also paused following the diagnosis of transverse myelitis in a participant, but the trial resumed after a safety review determined that the condition was not related to the vaccine.

Continue reading AstraZeneca’s COVID19 Vaccine Trial Paused Over Safety Concerns